REG - GENinCode PLC - Statement re: Silicon Valley Bank

GenincodeAnnouncement

13/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230313:nRSM6627Sa&default-theme=true

RNS Number : 6627S  GENinCode PLC  13 March 2023

GENinCode Plc

("GENinCode" or the "Company")

 

Statement re: Silicon Valley Bank

 

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the
closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at
SVB and does not have a banking relationship with SVB.

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                    Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                              Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode tests and technology provide physicians and patients with globally
leading preventative care and treatment strategies. GENinCode
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to prevent
cardiovascular disease.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRDGGDXDBBDGXD